文献检索分析

https://schlr.cnki.net/zn/Detail/index/GARJ2013/SJPD13110700500405

Journal|[J]Cancer Biotherapy and RadiopharmaceuticalsVolume 28, Issue 4. 2013. PP 274-82

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

作者: Vallera Daniel A; Zhang Bin; Gleason Michelle K; Oh Seunguk; Weiner Louis M; Kaufman Dan S; McCullar Valarie; Miller Jeffrey S; Verneris Michael R

作者背景: 1 Section of Molecular Cancer Therapeutics, Therapeutic Radiology-Radiation Oncology, University of Minnesota Masonic Cancer Center , Minneapolis, Minnesota.

DOI: 10.1089/cbr.2012.1329

全部来源

Mary Ann Liebert, Inc. JournalsPubMed Journal

摘要 / Abstract

A heterodimeric bispecific biological recombinant drug was synthesized by splicing DNA fragments from two fully humanized single-chain variable-fragment (scFV) antibody fragments forming a novel drug simultaneously recognizing the CD16 natural killer (NK) cell marker and the cancer marker epithelial cell adhesion molecule (EpCAM). The drug precipitously enhanced the killing of human carcinomas of the prostate, breast, colon, head, and neck even at very low effector:target ratios. The drug EpCAM16 rendered even nonactivated NK cell-proficient killers and activated them to kill via degranulation and cytokine production. Studies show that bispecific antibodies can be used to induce proficient killing of the carcinoma targets that ordinarily are resistant to NK-mediated killing. Apparently, the innate immune system can be effectively recruited to kill cancer cells using the bispecific antibody platform and EpCAM targeting.

收起

关键词 / Keywords

ADCC; Anti-CD16; Bispecific antibody; Carcinoma; Human NK cells

核心评价 / Indexed by

PMC; SCI; Scopus; WAJCI; MEDLINE; AHCI;

引证文献 / Cited by（被引用的文献）：引用本文作为参考依据的文献

国际期刊

共8条

• [1]

  Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response[J]. Carolyn Shembrey;Nicholas D. Huntington;Frédéric Hollande. Cancers. 2019(9)

• [2]

  Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects[J]. Barbara Bassani;Denisa Baci;Matteo Gallazzi;Alessandro Poggi;Antonino Bruno;Lorenzo Mortara. Cancers. 2019(4)

• [3]

  Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer[J]. Marco Greppi;Giovanna Tabellini;Ornella Patrizi;Simona Candiani;Andrea Decensi;Silvia Parolini;Simona Sivori;Silvia Pesce;Laura Paleari;Emanuela Marcenaro. International Journal of Molecular Sciences. 2019(4)

• [4]

  The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy[J]. Kevin Leone;Cristina Poggiana;Rita Zamarchi. Diagnostics. 2018(3)

• [5]

  Recent advances of bispecific antibodies in solid tumors[J]. Shengnan Yu;Anping Li;Qian Liu;Xun Yuan;Hanxiao Xu;Dechao Jiao;Richard G. Pestell;Xinwei Han;Kongming Wu. Journal of Hematology & Oncology. 2017(1)

• [6]

  CD133, Selectively Targeting the Root of Cancer[J]. Jörg U. Schmohl;Daniel A. Vallera;Tomas Girbes;David J. Fitzgerald. Toxins. 2016(6)

• [7]

  NK cells and cancer: you can teach innate cells new tricks[J]. Maelig G. Morvan;Lewis L. Lanier. Nature Reviews Cancer. 2016(Suppl 2)

• [8]

  Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?[J]. Joanie Del Bano;Patrick Chames;Daniel Baty;Brigitte Kerfelec. Antibodies. 2015(1)

Related articles / 相关文献

相似文献

作者发文

机构发文

关键词分析

相似文献（说明：与本文内容较接近的文献）

• [1]

  Joana Balça-Silva, Anália do Carmo, Hermínio Tão et al. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity[J]  Experimental Cell Research, 2018, 370(1)

• [2]

  Silva Anielle C.A., Silva Marcelo J.B., Rocha Annelise A. et al. Synergistic effect of simonkolleite with zinc oxide: PHYSICO-CHEMICAL properties and cytotoxicity in breast cancer cells[J]  Materials Chemistry and Physics, 2021(prepublish)

• [3]

  He Zhonglei, Charleton Clara, Devine Robert et al. Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma[J]  European Journal of Medicinal Chemistry, 2021, 224(prepublish)

• [4]

  Lin Lu, Donghui Zhang, Yu Xu et al. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1[J]  Biomedicine & Pharmacotherapy, 2018, 104

• [5]

  Jiang Qian, Zhihua Sun, Yiqiao Liu et al. Establishment of a cytotoxicity model of small cell lung cancer cell using the cell line NCI-H1688[J]  Toxicon, 2019, 158

• [6]

  J. Emerson, N. James, L.B. Beffa et al. Genomic analysis of immunosuppressive and pro-angiogenic genes in recombinant HE4 treated immune cells and implications for T cell cytotoxicity in ovarian cancer cell co-culture[J]  Gynecologic Oncology, 2019, 154(S1)

• [7]

  Nayoung Kim, Miju Kim, Sohyun Yun et al. MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1[J]  The Journal of Allergy and Clinical Immunology, 2014, 134(1)

• [8]

  Yang Jiong, Ding Shigang Chimeric RNA-binding protein-based killing switch targeting hepatocellular carcinoma cells[J]  Molecular Therapy - Nucleic Acids, 2021, 25

• [9]

  Mojgan Goudarzi, Masoud Salavati-Niasari, Marzieh Azizi et al. Green synthesis and characterization of MnCo 2 O 4 /Co 2 Mn 3 O 8 ceramic nanocomposites and investigation of their cytotoxicity on the 4T1 cells[J]  Composites Part B, 2019, 163

• [10]

  Suping Li, Qiao Jiang, Baoquan Ding et al. Anticancer Activities of Tumor-killing Nanorobots[J]  Trends in Biotechnology, 2019, 37(6)

共10页

• 1

• 2

• 3

• 4

• 5

• 10

末页

[1] 肿瘤和免疫异质性对抗癌免疫反应的影响[J]。卡罗琳·谢姆布雷；尼古拉斯·D·亨廷顿；弗里德里克·奥朗德。癌症。2019(9)

[2] 自然杀伤细胞作为肿瘤进展和血管生成的关键角色：将其促肿瘤活性转化为有效抗肿瘤作用的新旧工具【J】。芭芭拉·巴萨尼；德尼萨·巴奇；Matteo Gallazzi；亚历山德罗·波吉；安东尼诺·布鲁诺；洛伦佐·莫塔拉。癌症。2019(4)

[3] 增强抗肿瘤NK细胞功能治疗卵巢癌【J】。马可·格雷皮；乔瓦娜·塔贝利尼；帕特里氏奥奈拉菌；西蒙娜·坎迪亚尼；安德烈亚·德西西；Silvia Parolini；西蒙娜·西沃里；Silvia Pesce；劳拉·帕莱里；埃马努埃拉·马塞纳罗。国际分子科学杂志。2019(4)

[4] 循环肿瘤细胞与免疫系统的相互作用：从免疫逃逸到癌症免疫治疗【J】。凯文·利昂；克里斯蒂娜·波吉亚纳；丽塔·扎马奇。诊断。2018(3)

[5] 实体瘤双特异性抗体的研究进展[J]。俞胜南；李安平；刘谦；荀元；韩晓旭；焦德超；Richard G.Pestell；韩新伟；吴孔明。血液学和肿瘤学杂志。2017(1)

[6] CD133，选择性靶向癌症的根源[J]。Jörg U.Schmohl；Daniel A.Vallera；托马斯·吉尔布斯；大卫·J·菲茨杰拉德。毒素。2016(6)

[7] NK细胞和癌症：你可以教固有细胞新的技巧。Maelig G.Morvan；刘易斯·L·拉尼尔。《自然》杂志评论癌症。2016年（补充2）

[8] 接受癌症免疫治疗挑战：双特异性抗体，前进之路？[J] 。乔安妮·德尔巴诺；帕特里克·查姆斯；丹尼尔·巴蒂；Brigitte Kerfelec。抗体。2015(1)

[1]

Joana Balça-Silva，Anália do Carmo，Hermínio Tão等人。核仁蛋白在患者源性样本和胶质母细胞瘤细胞中表达，能够改善细胞内药物传递和细胞毒性【J】实验细胞研究，2018，370（1）

[2]

Silva Anielle C.A.、Silva Marcelo J.B.、Rocha Annelise A.等.硅孔雀石与氧化锌的协同作用：乳腺癌细胞的物理化学性质和细胞毒性[J].材料化学与物理，2021（预出版）

[3]

何中磊，Charleton Clara，Devine Robert等.产生活性氧的冷大气血浆增强吡唑啉酮对胶质母细胞瘤细胞的细胞毒性[J].欧洲药物化学杂志，2021，224（预出版）

[4]

林璐，张东辉，余旭等.miR-505通过直接靶向HMGB1抑制Akt通路增强阿霉素诱导的肝癌细胞毒性[J].生物医学与药物治疗，2018，104

[5]

姜倩，孙志华，刘一桥等。利用细胞系NCI-H1688建立小细胞肺癌细胞毒性模型【J】Toxicon，2019，158

[6]

J、 Emerson，N.James，L.B.Beffa等人。重组HE4处理的免疫细胞中免疫抑制和促血管生成基因的基因组分析及其对卵巢癌细胞共培养中T细胞毒性的影响【J】妇科肿瘤学，2019，154（S1）

[7]

Nayong Kim，Miju Kim，Sohyun Yun等人。MicroRNA-150通过靶向穿孔素-1调节自然杀伤细胞的细胞毒性【J】过敏与临床免疫学杂志，2014，134（1）

[8]

杨炯，丁世刚，基于RNA结合蛋白嵌合的肝癌细胞靶向杀伤开关【J】分子治疗-核酸，2021，25

[9]

Mojgan Goudarzi，Masoud Salavati Niasari，Marzieh Azizi等。MnCo 2 O 4/Co 2 Mn 3 O 8陶瓷纳米复合材料的绿色合成和表征及其对4T1细胞的细胞毒性研究【J】复合材料B部分，2019，163

[10]

李素平，乔江，丁保全等.纳米机器人的抗癌活性[J].生物技术趋势，2019，37（6）